Ann R Coll Surg Engl 2010; 92: 569-572 569Approximately 36,000 cases of colorectal cancer (CRC) are diagnosed per year in the UK.1 It is the third most common form of cancer among both males and females, and the second most common cause of cancer mortality in the UK. Preoperative anaemia is well recognised in patients presenting with colorectal cancer, with recent series suggesting a prevalence of iron deficiency in 60% 2 and an associated anaemia in up to 38% 3 of new presentations. Pre-operative anaemia is recognised as a predictive factor for blood transfusion, 4,5 as well as a predictor of adverse outcomes in surgical patients. Carson et al. 6 demonstrated that overall mortality increases as the haemoglobin concentration decreases, with even mild anaemia conferring an increased death risk.As well as becoming an increasingly scarce commodity, allogeneic blood transfusion confers potential risks to the recipient including immunomodulation, transfusion reaction and disease transmission. Peri-operative blood transfusion with allogeneic blood is also suggested to increase the risk of postoperative infectious complications. 7,8 A recent meta-analysis of 36 studies supports the evidence that perioperative blood transfusion has a detrimental effect on the recurrence of curable colorectal cancers although a direct causal relationship cannot be proven.
9While the benefits of long-term ferrous sulphate supplementation on iron-deficiency anaemia are well established, it is not known if short-course supplementation (2-3 weeks) impacts significantly on pre-operative haemoglobin levels